TP53 and diabetes mellitus: These results suggest that oncogenic signaling pathways could be reactivated by the induction of c-Myc and inhibition of the tumor suppressor functions of p53 and cav-1 in diabetes drug-treated HBlEpC cells under long-term hyperglycemic and hyperinsulinemic conditions.